Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-550-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) posted its earnings results on Friday, August, 10th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.63. View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
3 brokerages have issued 1-year price targets for Evofem Biosciences' shares. Their forecasts range from $9.00 to $11.00. On average, they expect Evofem Biosciences' share price to reach $9.6667 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.
Has Evofem Biosciences been receiving favorable news coverage?
Press coverage about EVFM stock has trended negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evofem Biosciences earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Evofem Biosciences.
Are investors shorting Evofem Biosciences?
Evofem Biosciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 883,400 shares, an increase of 5.0% from the July 31st total of 841,000 shares. Based on an average daily volume of 98,100 shares, the short-interest ratio is currently 9.0 days. Currently, 4.7% of the shares of the stock are sold short. View Evofem Biosciences' Current Options Chain.
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include Zymeworks (ZYME), Y-mAbs Therapeutics (YMAB), Esperion Therapeutics (ESPR), Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Cara Therapeutics (CARA), Amneal Pharmaceuticals (AMRX), ArQule (ARQL), Odonate Therapeutics (ODT), Omeros (OMER), TherapeuticsMD (TXMD), NextCure (NXTC), Homology Medicines (FIXX), Wave Life Sciences (WVE) and Phibro Animal Health (PAHC).
What other stocks do shareholders of Evofem Biosciences own?
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer (Age 49)
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Jason Abrams, Accounting Mang.
- Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)
Who are Evofem Biosciences' major shareholders?
Evofem Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Invesco Ltd. (25.35%), Heartland Advisors Inc. (1.83%), BlackRock Inc. (1.58%), Vanguard Group Inc. (1.41%), Northern Trust Corp (0.16%) and Charles Schwab Investment Management Inc. (0.10%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Kelly Culwell, Kim P Kamdar, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.
Which institutional investors are buying Evofem Biosciences stock?
EVFM stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Northern Trust Corp, Bank of New York Mellon Corp, Heartland Advisors Inc. and JPMorgan Chase & Co.. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $5.51.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $256.77 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.View Additional Information About Evofem Biosciences.
What is Evofem Biosciences' official website?
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
